Table 2. Correlations between lipoprotein characteristics and plasma oxidation with clinical features.

Pearson correlations of lipoprotein characteristics and plasma oxidation with clinical features in all subjects (lupus and control) or in lupus only. Statistically significant differences between groups are shaded and in bold; p < 0.05. Comparisons of lipoprotein profiles, MPO levels and cholesterol efflux capacity (CEC) between controls and SLE patients are shown. Differences in the estimated means between groups, standard error, and model R² are displayed. Variables indicated with an “*” were transformed (natural log-scale) prior to correlation calculation. Values indicated with “**” are adjusted as follows: CEC (%): Adjusted for HDL (n=50, R² =0.08); MPO (fmol/ml): Adjusted for Age, BMI, and LDL (n=49, r² =0.33); HDL-Cl-Tyr: Adjusted for BMI (n=59, R² =0.10); HDL-N-Tyr: Adjusted for cholesterol (n=54, R² =0.34); Plasma-3-Cl-Tyr: Adjusted for LDL (n=50, R² =0.21); Plasma-N-Tyr: Adjusted for LDL (n=50, R² =0.07). CRP = C-Reactive Protein, ESR = Erythrocyte Sedimentation Rate, SLEDAI = Systemic Lupus Erythematosus Disease Activity Index.

Pearson Correlations Among All Patients (n=60)
	MPO*	CE	HDL− Cl− Tyr*	HDLN− Tyr*	Plasma− Clxya Tyr *	Plasma− N-Tyr
Age (years)	r = −0.23, p=0.08	r = 0.11, p=0.39	r = 0.03, p=0.83	r = 0.07, p=0.61	r = −0.05, p=0.71	r = −0.02, p=0.89
Sex (males)	r = −0.21, p=0.11	r = −0.05, p=0.72	r = 0.21, p=0.12	r = 0.14, p=0.30	r = 0.08, p=0.54	r = 0.04, p=0.77
Body Mass Index* (kg/m2)	r = 0.20, p=0.13	r = −0.23, p=0.08	r = 0.31, p=0.02	r = 0.05, p=0.72	r = 0.18, p=0.18	r = 0.07, p=0.61
Cholesterol* (mg/dL)	r = −0.13, p=0.33	r = 0.14, p=0.31	r = −0.04, p=0.77	r = 0.58, p<0.01	r = −0.25, p=0.07	r = 0.23, p<0.10
Triglycerides* (mg/dL)	r = 0.11, p=0.44	r = −0.07, p=0.62	r = −0.14, p=0.32	r = 0.01, p=0.94	r = −0.02, p=0.90	r = −0.16, p=0.26
HDL* (mg/dL)	r = −0.25, p=0.08	r = 0.28, p<0.05	r = −0.15, p=0.28	r = 0.04, p=0.79	r = −0.17, p=0.22	r = 0.01, p=0.96
LDL (mg/dL)	r = −0.44, p<0.01	r = 0.18, p=0.22	r = −0.29, p=0.04	r = 0.12, p=0.41	r = −0.46, p<0.01	r = −0.27, p=0.06

Pearson Correlations Among Lupus Patients only (n=40)
	MPO*	CE	HDL− Cl− Tyr*	HDLN− Tyr*	Plasma− Cl− Tyr *	Plasma− N-Tyr
CRP* (mg/L)	r = 0.05, p=0.76	r = 0.18, p=0.27	r = 0.17, p=0.31	r = 0.11, p=0.52	r = 0.24, p=0.15	r = −0.16, p=0.34
ESR* (mm/hr)	r = 0.36, p=0.02	r = 0.06, p=0.71	r = −0.05, p=0.75	r = 0.19, p=0.26	r = 0.07, p=0.66	r = −0.14, p=0.40
SLEDAI	r = 0.14, p=0.39	r = 0.08, p=0.63	r = 0.15, p=0.34	r = 0.06, p=0.71	r = 0.15, p=0.36	r = 0.05, p=0.76
Steroid use	r= −0.09, p=0.59	r = 0.11, p=0.51	r = −0.20, p=0.22	r = −0.27, p=0.09	r = 0.11, p=0.49	r = 0.09, p=0.57
Antimalarial use	r = 0.03, p=0.83	r = 0.08, p=0.64	r = −0.08, p=0.62	r = 0.05, p=0.76	r = −0.20, p=0.23	r = 0.32, p<0.05
Statin use	r = −0.18, p=0.26	r = 0.13, p=0.42	r = −0.002, p=0.99	r = −0.01, p=0.95	r = 0.32, p<0.05	r = −0.12, p=0.48
Beta Blocker use	r = −0.07, p=0.66	r = 0.22, p=0.17	r = −0.15, p=0.36	r = −0.26, p=0.11	r = 0.16, p=0.32	r = −0.004, p=0.98
Ace inhibitor use	r = −0.06, p=0.70	r = 0.16, p=0.33	r = 0.09, p=0.59	r = 0.12, p=0.46	r = 0.01, p=0.96	r = −0.06, p=0.71

	Unadjusted Comparison				Adjusted** Comparison
	Controls	Lupus	p-value	Model R2	Controls	Lupus	p-value	Model R2
CEC (%)	9.2 ± 0.3	7.8 ± 0.2	0.0022	0.15	9.2 ± 0.3	8.0 ± 0.3	0.0073	0.21
MPO (fmol/ml)*	5.7 ± 0.1	6.0 ± 0.1	0.0005	0.19	5.8 ± 0.1	6.0 ± 0.1	0.0198	0.4
HDL 3- chlorotyrosine*	1.4 ± 0.4	5.4 ± 0.3	<0.0001	0.51	1.5 ± 0.4	5.4 ± 0.3	<0.0001	0.56
HDL 3- nitrotyrosine*	2.5 ± 0.4	4.2 ± 0.3	0.0003	0.2	2.6 ± 0.3	4.1 ± 0.2	0.0002	0.49
Plasma 3- chlorotyrosine*	0.4 ± 0.3	3.3 ± 0.2	<0.0001	0.49	0.3 ± 0.3	3.3 ± 0.2	<0.0001	0.62
Plasma 3- nitrotyrosine*	3.4 ± 0.2	5.7 ± 0.1	<0.0001	0.64	3.3 ± 0.2	5.7 ± 0.2	<0.0001	0.63